Literature DB >> 32537179

Association between urbanicity and surgical treatment among patients with primary glioblastoma in the United States.

Gino Cioffi1,2, David J Cote3,4,5, Quinn T Ostrom2,6, Carol Kruchko2, Jill S Barnholtz-Sloan1,2.   

Abstract

BACKGROUND: Glioblastoma (GB) is the most common and most lethal primary malignant brain tumor. Extent of surgical resection is one of the most important prognostic factors associated with improved survival. Historically, patients living in nonmetropolitan counties in the United States have limited access to optimal treatment and health care services. The aim of this study is to determine whether there is an association between urbanicity and surgical treatment patterns among US patients with primary GB.
METHODS: Cases with histologically confirmed, primary GB diagnosed between 2005 and 2015 were obtained from the Central Brain Tumor Registry of the United States (CBTRUS) in collaboration with the Centers for Disease Control and Prevention, and the National Cancer Institute. Multivariable logistic regression models were constructed to assess the association between urbanicity and receipt of surgical treatment (gross total resection [GTR]/subtotal resection [STR] vs biopsy only/none) and extent of resection (GTR vs STR), adjusted for age at diagnosis, sex, race, US regional division, and primary tumor site.
RESULTS: Patients residing in nonmetropolitan counties were 7% less likely to receive surgical treatment (odds ratio [OR] = 0.93, 95% CI: 0.89-0.96, P < .0001). Among those who received surgical treatment, metropolitan status was not significantly associated with receiving GTR vs STR (OR = 0.99, 95% CI: 0.94-1.04, P = .620).
CONCLUSIONS: Among US patients with GB, urbanicity is associated with receipt of surgical treatment, but among patients who receive surgery, urbanicity is not associated with extent of resection. These results point to potential differences in access to health care for those in nonmetropolitan areas that warrant further exploration.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  glioblastoma; gross total resection; subtotal resection; surgery; urbanicity

Year:  2020        PMID: 32537179      PMCID: PMC7274182          DOI: 10.1093/nop/npaa001

Source DB:  PubMed          Journal:  Neurooncol Pract        ISSN: 2054-2577


  21 in total

1.  Disparity of Colon Cancer Outcomes in Rural America: Making the Case to Travel the Extra Mile.

Authors:  Vignesh Raman; Mohamed A Adam; Megan C Turner; Harvey G Moore; Christopher R Mantyh; John Migaly
Journal:  J Gastrointest Surg       Date:  2019-05-31       Impact factor: 3.452

2.  Females have the survival advantage in glioblastoma.

Authors:  Quinn T Ostrom; Joshua B Rubin; Justin D Lathia; Michael E Berens; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2018-03-27       Impact factor: 12.300

3.  Disparities in access to neuro-oncologic care in the United States.

Authors:  Debraj Mukherjee; Hasan A Zaidi; Thomas Kosztowski; Kaisorn L Chaichana; Henry Brem; David C Chang; Alfredo Quiñones-Hinojosa
Journal:  Arch Surg       Date:  2010-03

4.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.

Authors:  M Lacroix; D Abi-Said; D R Fourney; Z L Gokaslan; W Shi; F DeMonte; F F Lang; I E McCutcheon; S J Hassenbusch; E Holland; K Hess; C Michael; D Miller; R Sawaya
Journal:  J Neurosurg       Date:  2001-08       Impact factor: 5.115

5.  Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.

Authors:  Christian Ewelt; Mathias Goeppert; Marion Rapp; Hans-Jakob Steiger; Walter Stummer; Michael Sabel
Journal:  J Neurooncol       Date:  2010-10-16       Impact factor: 4.130

6.  Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.

Authors:  Orin Bloch; Seunggu J Han; Soonmee Cha; Matthew Z Sun; Manish K Aghi; Michael W McDermott; Mitchel S Berger; Andrew T Parsa
Journal:  J Neurosurg       Date:  2012-10-05       Impact factor: 5.115

7.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

8.  Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma.

Authors:  Matthew M Grabowski; Pablo F Recinos; Amy S Nowacki; Jason L Schroeder; Lilyana Angelov; Gene H Barnett; Michael A Vogelbaum
Journal:  J Neurosurg       Date:  2014-09-05       Impact factor: 5.115

9.  Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014.

Authors:  Quinn T Ostrom; David J Cote; Mustafa Ascha; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

10.  Area-based socioeconomic position and adult glioma: a hierarchical analysis of surveillance epidemiology and end results data.

Authors:  Jesse J Plascak; James L Fisher
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

View more
  2 in total

1.  Racial/ethnic disparities in treatment pattern and time to treatment for adults with glioblastoma in the US.

Authors:  Quinn T Ostrom; Halle L Krebs; Nirav Patil; Gino Cioffi; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2021-03-23       Impact factor: 4.130

2.  Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas.

Authors:  Gi-Ming Wang; Gino Cioffi; Nirav Patil; Kristin A Waite; Robert Lanese; Quinn T Ostrom; Carol Kruchko; Michael E Berens; James R Connor; Justin D Lathia; Joshua B Rubin; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2022-02-01       Impact factor: 13.029

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.